Lupin Seeks Partners For Biosimilars And Oncology Research
FY22 Guidance Lowered
Buoyed by a $50m milestone payment for a MEK inhibitor licensed to Boehringer Ingelheim and in a bid to mitigate the burn on profits, Lupin is considering partnerships for biosimilars, specialty products and other NCEs with recently spun-off oncology assets being first in line for a deal. But FY22 earnings guidance has been lowered.
You may also be interested in...
Biosimilars players are gaining an increasing foothold in the off-patent industry, as demonstrated by the final part of our annual Top 50 ranking.
India’s Glenmark had noted recently that market entry was forthcoming for a generic Boehringer Ingelheim’s Spiriva Handihaler, and has now delivered with an initial UK launch.
Lupin has gained a head start on other US generic rivals to Sunovion’s Brovana treatment for COPD with the launch of an authorized generic version of arformoterol tartrate inhalation solution.